GlassScriptPhysician profile
Robert M Ortiz
NPI 1851430383
$9,494.69
in general payments reported to CMS, 2019-2025
44 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,154 · 2022: $2,003 · 2023: $2,011 · 2024: $2,163 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,337.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $790.39 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $783.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $771.02 | 2021-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $760.42 | 2021-2025 | |
| Lilly USA, LLC | $631.91 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $584.66 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $514.53 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $457.30 | 2021-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $446.19 | 2021-2024 | |
| Pfizer INC. | $428.93 | 2021-2025 | |
| Gilead Sciences, INC. | $422.74 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $391.16 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $230.54 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $230.31 | 2021-2022 | |
| Abbott Laboratories | $227.60 | 2023-2025 | Freestyle Libre 3 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $221.49 | 2021-2024 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.78 | 2022-2025 | Xifaxan, Trulance |
| Averitas Pharma INC. | $168.02 | 2023-2025 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.19 | 2021-2024 | Jardiance, Tradjenta |
| Dexcom, INC. | $111.36 | 2022-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $98.89 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $84.71 | 2021 | |
| Neurocrine Biosciences, INC. | $81.38 | 2024-2025 | Ingrezza |
| Eisai INC. | $78.09 | 2021-2025 | |
| Exact Sciences Corporation | $62.38 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $59.82 | 2021-2025 | Nexletol |
| Medtronic, INC. | $59.46 | 2025 | Symplicity G3 |
| Kowa Pharmaceuticals America, INC. | $59.01 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $53.21 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $47.30 | 2021-2024 | Trintellix |
| Corium, LLC | $45.20 | 2023 | Azstarys |
| Daiichi Sankyo INC. | $35.74 | 2024-2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $33.83 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $33.16 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $23.29 | 2025 | Inspire |
| Boston Scientific Corporation | $21.64 | 2022 | |
| Radius Health, INC. | $20.60 | 2025 | Tymlos |
| Viiv Healthcare Company | $20.28 | 2021 | |
| Horizon Therapeutics Plc | $17.61 | 2022 | |
| Corcept Therapeutics | $16.34 | 2025 | Korlym |
| Grifols USA, LLC | $16.24 | 2021 | |
| Seqirus USA INC | $14.52 | 2025 | Flucelvax |
| Axsome Therapeutics, INC. | $8.90 | 2025 | Sunosi |
| Genentech USA, INC. | $3.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.